CCAT2 and breast carcinoma: Thus, these findings suggest that CCAT2 is involved in tamoxifen resistance in breast cancer cells and may provide a novel therapeutic molecule in the treatment of breast cancer and/or tamoxifin-resistant breast cancer patients.